Search for European Projects

7 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets (COMPACT)

Start date: Nov 1, 2012, End date: Oct 31, 2017,

Most biopharmaceuticals (BP) currently on the market are recombinant proteins which are parenterally administered. These would benefit from more patient-friendly routes of administration. Moreover, new classes of BP (e.g. siRNA, miRNA, DARPins) with specificity for intracellular targets hold promise but await the advent of efficient delivery systems before their potential can be realised into ther ...
Read Project

 22

 FINISHED 

DARPin Targeted Magnetic Hyperthermic Therapy for Glioblastoma (DARTRIX)

Start date: Mar 1, 2012, End date: Feb 28, 2017,

"DARTRIX, ‘DARPin Targeted RX (therapy)’ is a multidisciplinary collaborative project that will develop high-affinity protein scaffolds to create a new generation of targeted therapeutics for the treatment of glioblastoma. There is great need; glioblastoma is virtually incurable and most patients die within 12 months of diagnosis. DARPins are small, non-immunoglobulin human protein scaffolds that ...
Read Project

 8

 FINISHED 

General light triggered switches and sensors for studying proteins inside the cell (NEXTBINDERS)

Start date: May 1, 2011, End date: Apr 30, 2016,

"The overall objective is to develop general strategies for creating sensors and switches that work inside cells. They will be engineered from Designed Ankyrin Repeat Proteins (DARPins) as general binding proteins that function inside cells and can be generated against any target by selection and directed evolution. Light-triggered switches will be engineered by placing a LOV domain from phototrop ...
Read Project

 1

 FINISHED 

Protein Binders for Characterisation of Human Proteome Function: Generation, Validation, Application (AFFINOMICS)

Start date: Apr 1, 2010, End date: Mar 31, 2015,

The Affinomics programme aims to leverage existing efforts in Europe to generate large-scale resources of validated protein-binding molecules (‘binders’) as affinity reagents for characterisation of the human proteome and to apply them in comprehensive structural and functional analyses of protein expression, interactions and complexes. Proteome targets will be focused on five categories of inter- ...
Read Project

 20

 FINISHED 

Lessons from the genome of Escherichia coli: understanding heterologous expression of eukaryotic internal membrane proteins in bacterial cells (BioIMPrOve)

Start date: Dec 1, 2012, End date: Nov 30, 2014,

Eukaryotic cells express integral membrane proteins (IMP) that exchange substances with their environment or receive signals in the form of small molecules, peptides or proteins. Most human IMPs are inherently difficult to study, because of complications in obtaining adequate amounts of stable and functional proteins. G protein-coupled receptors (GPCRs) are the largest IMP family in the human geno ...
Read Project

 1

 FINISHED 

Advanced affinity tools and technologies for high throughput studies of the human proteome (AffinityProteome)

Start date: Mar 1, 2009, End date: Feb 29, 2012,

High specificity affinity reagents (‘binders’) are essential probes for proteome research, enabling the detection and localisation of multiple proteins in tissues and fluids in health and disease, through the application of binder-based technologies (affinity proteomics). This proposal links the high throughput production of quality-controlled, recombinant binding molecules of different types (ant ...
Read Project

 10

 FINISHED 

Conversion of integral membrane receptors into soluble forms (GPCRs)

Start date: Sep 1, 2009, End date: Aug 31, 2011,

G-protein coupled receptors (GPCRs) are cell surface receptors that mediate the cellular responses to an enormous diversity of endogenous signaling molecules as well as environmental signals. GPCRs are a major target for the pharmaceutical industry as is reflected by the fact that more than 50% of all medicines available today act on a GPCR and represent about a quarter of the top-selling drugs wo ...
Read Project

 1